Reports Q4 revenue $263.166M, consensus $244.59M. "2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. We accelerated our growth, diversified our portfolio, and delivered record revenues and profits which created additional free cash flows," said Mary Anne Heino, President and Chief Executive Officer of Lantheus. "In 2023, PYLARIFY, the #1 PSMA PET imaging agent and DEFINITY, the #1 ultrasound enhancing agent, will continue to deliver value for our patients, healthcare professionals, employees, and shareholders."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LNTH:
- Lantheus Blasts Up as Earnings Impress
- Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
- Lantheus presents data on piflufolastat F 18 at 2023 ASCO symposium
- Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
- Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
